CN112370607B - Insulin pump therapeutic instrument - Google Patents

Abstract

A spectrum online blood sugar analyzer and an insulin pump control method relate to an insulin pump therapeutic instrument for diabetics. The invention mainly aims to solve the problems that the existing insulin pump can only reflect the blood sugar condition at the time of blood sampling and can not continuously measure the blood sugar level. The online analysis technology of the spectrum is utilized to analyze and measure the blood sugar concentration in the human body in vitro, and the insulin infusion dosage is adjusted and the treatment scheme is optimized according to the continuous and uninterrupted detection and analysis data of the online analyzer and by combining with the artificial intelligent systems such as the remote medical support and the like. The data are transmitted to the central module through a wireless data network, the central module controls the program controller PLC, and the PLC controls the operation of the insulin pump. The insulin pump, the insulin storage bottle and the program controller PLC are integrated in the portable box body, and two or more insulin storage bottles are arranged in the box body.

Description

Insulin pump therapeutic instrument

Technical Field

The invention relates to an insulin pump therapeutic instrument for diabetics.

Background

Diabetes is a chronic disease which is harmful to human populations and serious, is one of four major non-infectious diseases determined by the world health organization, has an increasing incidence rate year by year and has an increasing growth rate. Acute and chronic complications of diabetes, especially chronic complications, can almost affect all organs of a human body, have high self-mutilation and lethality rate, greatly influence the life quality and the life expectancy of patients, and bring heavy burden to families and society.

To improve the clinical outcome of diabetic patients, the principles of early, long-term, comprehensive and individualized treatment are currently emphasized. The goal of treatment is to bring the patient's blood glucose to or near normal levels, eliminate the symptoms of glucotoxicity and diabetes, correct metabolic disorders, control co-morbid hypertension, hypercoagulative states, prevent and delay the occurrence of complications, maintain good health and labor capacity, prolong life, and reduce the rate of mortality.

Blood sugar is regulated by two parts of insulin secretion, namely, the insulin secretion in a continuous basic state, which is used for inhibiting the output of hepatic glucose and keeping the balance with basic blood sugar so as to maintain the fluctuation of the blood sugar within a certain narrow range. Insulin secretion during meal, carbohydrate is absorbed into blood through gastrointestinal tract after meal, insulin secretion is increased, utilization and storage of glucose are promoted, and hepatic glucose output is inhibited so as to deal with increase of postprandial blood sugar. Therefore, patients requiring insulin therapy need to be supplemented not only for postprandial insulin deficiency but also for basal conditions.

In the basal state, physiological insulin secretion is pulsed, approximately 0.5-1 unit per hour, and usually basal insulin secretion decreases from midnight to 3 am and then increases to accommodate dawn phenomena. Under the stimulation of high blood sugar at meal, the insulin can be secreted to 5 units per hour, the daily insulin secretion of a normal person is about 18-32 units, and the metabolic pathway of endogenous insulin is different from that of exogenous insulin. Endogenous insulin firstly enters the liver through a portal vein system, 50-60% of the endogenous insulin is metabolized and eliminated in the liver, namely, the first pass effect, and exogenous insulin directly enters blood circulation after being injected to play a biological effect.

According to the kinetic characteristics of the drug, clinically used insulin preparations are classified into ultra-short-acting insulin, intermediate-acting insulin and long-acting insulin.

At present, the basic secretion of insulin in vivo is simulated, a portable insulin pump is utilized to continuously infuse trace insulin to the subcutaneous tissue, so that the hepatic glucose generation is adapted to the utilization of peripheral tissues, the insulin release amount is obviously increased during meal, the insulin secretion related to meal is simulated, and the subcutaneous accumulation of a large amount of insulin is avoided. The above method is consistent with multiple daily injections of insulin in blood glucose control. The insulin pump is convenient to treat (without pre-meal injection or using an injection pen), so that the life of a patient has more freedom. The traditional Chinese medicine is a more popular, advanced and better curative treatment method on the market at present. However, this method also has drawbacks and disadvantages: 1, after purchasing an insulin pump, a patient needs to take blood for one week under the skin continuously, analyze the blood sugar content (manual work), and then make a control model of the insulin infusion quantity according to the blood sugar analysis and measurement result. The model has the defects that the model can only reflect the blood sugar change condition during blood taking, cannot represent the blood sugar change condition in the future time period, has limitation and blindness, and increases the infection probability and pain of patients by continuously taking blood. 2, in order to correct blood sugar change data, the method provides a portable blood sugar meter, but only a patient can take blood by using a test paper strip discontinuously and insert the test paper strip into the blood sugar meter for detection, but also can only reflect the blood sugar condition at the time of blood taking, can not measure the blood sugar level continuously, can not completely simulate physiological insulin secretion, and can not effectively avoid peripheral hyperinsulinemia, diabetic ketoacidosis and hypoglycemia. 3, the requirement on users is high, and the price is high.

Disclosure of Invention

The invention aims to solve the technical problem of providing an insulin pump therapeutic instrument which can accurately and timely analyze the blood sugar concentration in a body of a patient under the conditions of no pain, no wound and no infection risk, and can switch basic insulin and instant insulin at any time to realize the optimal curative effect.

The above object is achieved by: the online analysis technology of the spectrum is utilized to analyze and measure the blood sugar concentration in the human body in vitro, and the insulin infusion dosage is adjusted and the treatment scheme is optimized according to the continuous and uninterrupted detection and analysis data of the online analyzer and by combining with the artificial intelligent systems such as the remote medical support and the like. The data are transmitted to the central module through a wireless data network, the central module controls the program controller PLC, and the PLC controls the operation of the insulin pump. The insulin pump, the insulin storage bottle and the program controller PLC are integrated in the portable box body, two or more insulin storage bottles are arranged in the box body, and the insulin types can be switched on line at any time according to treatment needs.

The online blood glucose analyzer comprises an online spectrum blood glucose analyzer, wherein the online spectrum blood glucose analyzer consists of an arc lamp, a display containing a central module and a bracelet, and the arc lamp is provided with a miniature lithium battery as a power supply; the arc lamp is located on the palm side when worn and the display is located on the back hand side. The center module is integrated on a chip of 7.5 mm multiplied by 7.5 mm, a medium-scale integrated circuit is manufactured by utilizing a micro-processing technology, an independent lithium battery power supply is arranged in the center module, and a photoelectric detector (namely a photomultiplier) processing circuit, a front-end circuit, a display screen and a Bluetooth communication device are also arranged in the center module; the display screen serves as a data display screen and a telephone (wireless) display screen.

Still include the insulin pump box body, the insulin pump box body is equipped with the different kind of insulin bottle of a plurality of in, all installs an insulin bottle control valve on the transfer line of every insulin bottle, these transfer lines all link to each other with the insulin pump import, install insulin control governing valve on insulin pump exit linkage's the transfer line, insulin bottle control valve and insulin pump and insulin control governing valve all be connected with program controller PLC through the wire, program controller PLC provides electric power by the lithium battery power supply who installs in the insulin pump box body, still is equipped with the bluetooth interface on the insulin pump box body. The insulin pump box body is worn on the waist.

The insulin pump control method comprises the following steps: an arc lamp located on the palm side illuminates the venous blood vessels in the arm, where blood glucose absorbs light of a specific wavelength, forming a characteristic absorption spectrum of blood glucose, which is received by a photodetector (i.e., photomultiplier tube) in the central module on the back of the hand and converted into an electrical signal. The electric signal is compared, calculated and processed by a front-end circuit (containing a data system such as a standard blood sugar concentration database and the like) and a processing circuit (containing a microprocessor and having the function of a small computer) in the central module to obtain the instant concentration data of the blood sugar in the veins of the human body. Blood glucose concentration data passes through bluetooth communication technology and sends the program controller PLC of insulin pump box body to, and program controller PLC controls the valve switch of insulin bottle and the aperture of insulin pump flow control governing valve, controls the variety of insulin promptly and the human quantity of pump income.

Telemedicine support may also be performed: after the doctor passes the identity authentication, the central module communication interface remotely accesses the image analysis measurement data and sends out instructions to optimally adjust the variety of the insulin used by the patient and the amount of the insulin pumped into the human body, the treatment of the patient is placed in the long-term and continuous monitoring of the doctor, and the manual intervention and the optimal adjustment are timely and effectively carried out, so that the patient can obtain satisfactory treatment experience and the optimal treatment effect.

The instant blood sugar analysis data and doctor instructions are transmitted to the program controller PLC through the Bluetooth communication technology to adjust and control the insulin varieties and the quantity pumped into the human body.

The control principle of the program controller PLC is as follows: when the concentration of the venous blood sugar rises, the PLC controls the insulin pump regulating valve to increase the opening degree, the quantity of the insulin pumped into the human body increases, on the contrary, when the concentration of the blood sugar falls, the PLC controls the insulin pump regulating valve to decrease the opening degree, and the quantity of the insulin pumped into the human body decreases. A preset ratio relationship exists between the blood sugar concentration and the amount of insulin pumped into a human body, and the doctor orders to adjust the ratio relationship and the variety of the insulin so as to realize the optimal curative effect.

The insulin pump is made of polytetrafluoroethylene engineering plastic, the pressure of the pump outlet is 0.005MPa (G) -0.015 MPa (G), and the flow rate is 0.3-8 unit insulin amount/hour.

The insulin bottle is formed by mixing transparent nylon or polymethyl methacrylate and polyisophthaloyl metaphenylene diamine slices with rare earth, and has the outstanding performances of heat insulation and high strength, and when the rare earth can be one or more of lanthanum, praseodymium, neodymium, erbium and yttrium, the proportion is not limited when the rare earth is mixed with a plurality of lanthanum, praseodymium, neodymium, erbium and yttrium. The blending amount of the rare earth is 0.5-3% (wt).

The insulin infusion tube is prepared by mixing polycarbonate, polyvinyl alcohol or high-density linear polyethylene slices with rare earth, has the performances of high strength, heat insulation and the like, wherein the rare earth can be one or a mixture of lanthanum, praseodymium, neodymium, erbium and yttrium, the proportion is not limited when the rare earth is mixed with a plurality of lanthanum, praseodymium, neodymium, erbium and yttrium, and the mixing amount of the rare earth is 0.5-1.5% (wt).

The electromagnetic valve and the regulating valve are made of nylon engineering plastics.

The type of insulin in the insulin bottle can be ultra-short acting, intermediate acting or ultra-long acting or a mixture thereof.

Detection range of the spectrum online blood glucose analyzer: 0.1-1000mg/de, and the standard deviation SD of repeatability is less than or equal to 2; absolute error of full-scale measurement is less than or equal to +/-0.1% FS.

The invention has the advantages that: the invention makes up the defects of the current insulin pump therapy on the market, can better simulate the physiological insulin secretion and achieves the best treatment effect. The central module and the program controller PLC can continuously measure the blood sugar concentration of the human body, and timely and accurately adjust the insulin infusion amount according to the actual data change of the blood sugar concentration of the human body. And the treatment scheme can be timely optimized by combining the diagnosis of doctors.

The in-vitro online analysis method adopted by the invention can accurately and timely analyze the blood sugar concentration in vivo under the conditions of no pain, no wound and no infection risk of patients. The invention is provided with a plurality of insulin storage bottles, and can switch basic insulin and instant insulin such as ultra-short-acting insulin, intermediate-acting insulin and long-acting insulin at any time according to the sorting detection data of the central module, thereby realizing the best curative effect and effectively avoiding peripheral hyperinsulinemia, diabetic ketoacidosis, hypoglycemia and the like.

The blood sugar analyzer has small volume, the blood sugar analysis data is timely and accurate, and the blood sugar data at the analyzed position can be used as the basis for diagnosis and treatment of doctors.

Description of the drawings:

FIG. 1 is a schematic diagram of the structure of the spectral on-line blood glucose analyzer of the present invention;

FIG. 2 is a schematic diagram of the layout of the central module and the control of the insulin pump according to the present invention.

The specific implementation mode is as follows:

the invention is further described below in connection with fig. 1 and 2;

the online analysis technology of the spectrum is utilized to analyze and measure the blood sugar concentration in the human body in vitro, and the insulin infusion dosage is adjusted and the treatment scheme is optimized according to the continuous and uninterrupted detection and analysis data of the online analyzer and by combining with the artificial intelligent systems such as the remote medical support and the like. The data are transmitted to the central module through a wireless data network, the central module controls the program controller PLC, and the PLC controls the operation of the insulin pump. The insulin pump, the insulin storage bottle and the program controller PLC are integrated in the portable box body, two or more insulin storage bottles are arranged in the box body, and the insulin types can be switched on line at any time according to treatment needs.

The online blood glucose analyzer comprises an online spectrum blood glucose analyzer, wherein the online spectrum blood glucose analyzer consists of anarc lamp 1, adisplay 2 containing a central module and abracelet 3, and the arc lamp is provided with a miniature lithium battery as a power supply; the arc lamp is located on the palm side when worn and the display is located on the back hand side. Thecentral module 4 is integrated on a chip of 7.5 mm multiplied by 7.5 mm, a medium-scale integrated circuit is manufactured by utilizing a micro-processing technology, an independent lithium battery power supply is arranged in the central module, and a photoelectric detector (namely a photomultiplier) processing circuit, a front-end circuit, a display screen and a Bluetooth communication device are also arranged in the central module; the display screen serves as a data display screen and a telephone (wireless) display screen.

Still include the insulin pump box body, insulin pump box body is equipped with the different kind of insulin bottle 5 of a plurality of in the box body, all installs an insulinbottle control valve 6 on thetransfer line 7 of every insulin bottle, these transfer lines all link to each other with the import ofinsulin pump 8, install insulincontrol governing valve 9 on insulin pump exit linkage's the transfer line, insulin bottle control valve and insulin pump and insulin control governing valve all be connected with program controller PLC through the wire, program controller PLC provides electric power by the lithium battery power supply of installing in insulin pump box body, still is equipped with the bluetooth interface on the insulin pump box body. The insulin pump box body is worn on the waist.

The insulin pump control method comprises the following steps: an arc lamp located on the palm side illuminates the venous blood vessels in the arm, where blood glucose absorbs light of a specific wavelength, forming a characteristic absorption spectrum of blood glucose, which is received by a photodetector (i.e., photomultiplier tube) in the central module on the back of the hand and converted into an electrical signal. The electric signal is compared, calculated and processed by a front-end circuit (containing a data system such as a standard blood sugar concentration database) and a processing circuit (containing a microprocessor and having the function of a small computer) in the central module to obtain the instant concentration data of the blood sugar in the veins of the human body. Blood glucose concentration data passes through bluetooth communication technology and sends the program controller PLC of insulin pump box body to, and program controller PLC controls the valve switch of insulin bottle and the aperture of insulin pump flow control governing valve, controls the variety of insulin promptly and the human quantity of pump income.

Telemedicine support may also be performed: after the doctor passes the identity authentication, the central module communication interface remotely accesses the image analysis measurement data and sends out instructions to optimally adjust the variety of the insulin used by the patient and the amount of the insulin pumped into the human body, the treatment of the patient is placed in the long-term and continuous monitoring of the doctor, and the manual intervention and the optimal adjustment are timely and effectively carried out, so that the patient can obtain satisfactory treatment experience and the optimal treatment effect.

The instant blood sugar analysis data and doctor instructions are transmitted to the program controller PLC through the Bluetooth communication technology to adjust and control the insulin varieties and the quantity pumped into the human body.

The control principle of the program controller PLC is as follows: when the concentration of the venous blood sugar rises, the PLC controls the insulin pump regulating valve to increase the opening degree, the quantity of the insulin pumped into the human body increases, otherwise, when the concentration of the blood sugar falls, the PLC controls the insulin pump regulating valve to decrease the opening degree, and the quantity of the insulin pumped into the human body decreases. A preset ratio relationship exists between the blood sugar concentration and the amount of insulin pumped into a human body, and the doctor commands can adjust the ratio relationship and the variety of the insulin to realize the optimal curative effect.

The insulin pump is made of polytetrafluoroethylene engineering plastic, the pressure of the pump outlet is 0.005MPa (G) -0.015 MPa (G), and the flow rate is 0.3-8 unit insulin amount/hour.

The insulin bottle is formed by mixing transparent nylon or polymethyl methacrylate and polyisophthaloyl metaphenylene diamine slices with rare earth, and has the outstanding performances of heat insulation and high strength, and when the rare earth can be one or more of lanthanum, praseodymium, neodymium, erbium and yttrium, the proportion is not limited when the rare earth is mixed with a plurality of lanthanum, praseodymium, neodymium, erbium and yttrium. The blending amount of the rare earth is 0.5-3% (wt).

The insulin infusion tube is prepared by mixing polycarbonate, polyvinyl alcohol or high-density linear polyethylene slices with rare earth, has the performances of high strength, heat insulation and the like, wherein the rare earth can be one or a mixture of lanthanum, praseodymium, neodymium, erbium and yttrium, the proportion is not limited when the rare earth is mixed with a plurality of lanthanum, praseodymium, neodymium, erbium and yttrium, and the mixing amount of the rare earth is 0.5-1.5% (wt).

The electromagnetic valve and the regulating valve are made of nylon engineering plastics.

The type of insulin in the insulin bottle can be ultra-short acting, intermediate acting or ultra-long acting or a mixture thereof.

Detection range of the spectrum online blood glucose analyzer: 0.1-1000mg/de, and the standard deviation SD of repeatability is less than or equal to 2; absolute error of full-scale measurement is less than or equal to +/-0.1% FS.

The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and variations can be made without departing from the technical principle of the present invention, and these modifications and variations should also be regarded as the protection scope of the present invention.

Claims (3)

1. An insulin pump therapeutic instrument, characterized by: the online blood glucose analyzer comprises an online spectrum blood glucose analyzer, wherein the online spectrum blood glucose analyzer consists of an arc lamp, a display containing a central module and a bracelet, and the arc lamp is provided with a miniature lithium battery as a power supply; when worn, the arc lamp is positioned at the palm side, and the display is positioned at the back side of the hand; the center module is integrated on a chip and is made into a medium-scale integrated circuit by utilizing a micromachining technology, an independent lithium battery power supply is arranged in the center module, and a photoelectric detector processing circuit, a front-end circuit, a display screen and a Bluetooth communication device are arranged in the center module; the display screen is used as a data display screen and a telephone display screen;

the insulin pump comprises an insulin pump box body, a plurality of insulin bottles of different types are arranged in the insulin pump box body, an insulin bottle control valve is arranged on a liquid conveying pipe of each insulin bottle, the liquid conveying pipes are connected with an insulin pump inlet, an insulin control adjusting valve is arranged on the liquid conveying pipe connected with an insulin pump outlet, the insulin bottle control valve, the insulin pump and the insulin control adjusting valve are connected with a program controller PLC through leads, the program controller PLC is powered by a lithium battery power supply arranged in the insulin pump box body, and a Bluetooth interface is further arranged on the insulin pump box body;

the insulin in the insulin bottle is ultra-short-acting, medium-acting or ultra-long-acting or a mixture thereof;

the control method of the insulin pump comprises the following steps: the arc lamp at the palm side irradiates vein blood vessels in the arm, and blood sugar in the vein blood vessels absorbs light with a specific wavelength to form a characteristic absorption spectrum of the blood sugar, and the characteristic absorption spectrum is received by a photoelectric detector in the central module on the back of the hand and is converted into an electric signal; the electric signals are compared, calculated and processed by a front-end circuit and a processing circuit in the central module to obtain instant concentration data of blood sugar in the veins of the human body; blood glucose concentration data passes through bluetooth communication technology and sends the program controller PLC of insulin pump box body to, and program controller PLC controls the valve switch of insulin bottle and the aperture of insulin pump flow control governing valve, controls the variety of insulin promptly and the human quantity of pump income.

2. An insulin pump therapeutic apparatus according to claim 1, wherein: the insulin pump is made of polytetrafluoroethylene engineering plastic, the pressure of the pump outlet is 0.005MPa (G) -0.015 MPa (G), and the flow rate is 0.3-8 unit insulin amount/hour.

3. An insulin pump treatment instrument as claimed in claim 1, wherein: the electromagnetic valve and the regulating valve are made of nylon engineering plastics.

Images